PD-1单抗联合化疗在食管癌治疗中的有效性及安全性分析  

Efficacy and safety analysis of PD-1 monoclonal antibody combined with chemotherapy in the treatment of esophageal cancer

作　　者：申晓梅[1] 薛锦[2] 刘兴祥[1] SHEN Xiaomei;XUE Jin;LIU Xingxiang(Oncology Department,Taizhou Second People’s Hospital,Jiangsu,Taizhou 225300,China;Department of Chest Surgery,Taizhou Second People’s Hospital,Jiangsu,Taizhou 225300,China)

机构地区：[1]江苏省泰州市第二人民医院肿瘤科,江苏泰州225300 [2]江苏省泰州市第二人民医院胸外科,江苏泰州225300

出　　处：《中国医药科学》2024年第20期144-147,共4页China Medicine And Pharmacy

基　　金：江苏省泰州市第五期“311工程”第二层次培养对象科研资助项目(RCPY202031)。

摘　　要：目的探讨程序性死亡受体1(PD-1)单抗联合化疗在食管癌治疗中的有效性及安全性。方法选择2022年1月至2023年12月泰州市第二人民医院收治的80例食管癌患者为研究对象,按照随机数表法分为研究组与对照组,每组各40例。对照组患者给予紫杉醇(白蛋白结合型)+顺铂化疗,研究组患者给予PD-1单抗联合紫杉醇(白蛋白结合型)+顺铂化疗。比较两组患者PD-1、程序性死亡-配体1(PD-L1)水平,免疫功能指标(CD3~+、CD4~+、CD4~+/CD8~+),临床疗效以及不良反应总发生率。结果研究组患者PD-1、PD-L1水平明显低于对照组,差异有统计学意义(P<0.05);研究组患者免疫功能指标明显高于对照组,差异有统计学意义(P<0.05);研究组患者治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);研究组患者不良反应总发生率明显低于对照组,差异有统计学意义(P<0.05)。结论采用PD-1单抗联合紫杉醇+顺铂化疗能够有效提升食管癌患者临床疗效与免疫功能,并降低患者PD-1、PD-L1水平和不良反应发生率,值得推广应用。Objective To explore the efficacy and safety of programmed death receptor 1(PD-1)monoclonal antibody combined with chemotherapy in the treatment of esophageal cancer.Methods A total of 80 esophageal cancer patients from the Taizhou Second People’s Hospital from January 2022 to December 2023 were selected as the subjects of this study.They were divided into a study group and a control group according to random number table method,with 40 cases in each group.The esophageal cancer patients in the control group were treated with paclitaxel(albumin binding)+cisplatin,while the esophageal cancer patients in the study group were treated with PD-1 monoclonal antibody combined with paclitaxel(albumin binding)+cisplatin.The levels of PD-1,programmed death-ligand-1(PD-L1),immune function(CD3+,CD4+and CD4+/CD8+),therapeutic efficacy and the total incidence rate of adverse reactions were compared between the two groups.Results The levels of PD-1 and PD-L1 of the patients in the study group were significantly lower than those of the control group,and the difference was statistically significant(P<0.05).The immune function indexes of the patients in the study group were significantly higher than those of the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment of the patients in the study group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The total incidence rate of adverse reactions of the patients in the study group was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The use of PD-1 monoclonal antibody combined with paclitaxel+cisplatin chemotherapy can effectively improve the clinical efficacy and immune function of esophageal cancer patients,and reduce the levels of PD-1,PD-L1 and the incidence of adverse reactions in patients,which is worthy of popularization and application.

关 键 词：PD-1单抗 紫杉醇(白蛋白结合型) 顺铂 食管癌 有效性 安全性 

分 类 号：R735.1[医药卫生—肿瘤]